001     120514
005     20240228145450.0
024 7 _ |a 10.1136/gutjnl-2016-313314
|2 doi
024 7 _ |a pmid:28336518
|2 pmid
024 7 _ |a 0017-5749
|2 ISSN
024 7 _ |a 1468-3288
|2 ISSN
024 7 _ |a altmetric:18147847
|2 altmetric
037 _ _ |a DKFZ-2017-00943
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Breitkopf-Heinlein, Katja
|b 0
245 _ _ |a BMP-9 interferes with liver regeneration and promotes liver fibrosis.
260 _ _ |a London
|c 2017
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1533813423_16775
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Bone morphogenetic protein (BMP)-9, a member of the transforming growth factor-β family of cytokines, is constitutively produced in the liver. Systemic levels act on many organs and tissues including bone and endothelium, but little is known about its hepatic functions in health and disease.Levels of BMP-9 and its receptors were analysed in primary liver cells. Direct effects of BMP-9 on hepatic stellate cells (HSCs) and hepatocytes were studied in vitro, and the role of BMP-9 was examined in acute and chronic liver injury models in mice.Quiescent and activated HSCs were identified as major BMP-9 producing liver cell type. BMP-9 stimulation of cultured hepatocytes inhibited proliferation, epithelial to mesenchymal transition and preserved expression of important metabolic enzymes such as cytochrome P450. Acute liver injury caused by partial hepatectomy or single injections of carbon tetrachloride (CCl4) or lipopolysaccharide (LPS) into mice resulted in transient downregulation of hepatic BMP-9 mRNA expression. Correspondingly, LPS stimulation led to downregulation of BMP-9 expression in cultured HSCs. Application of BMP-9 after partial hepatectomy significantly enhanced liver damage and disturbed the proliferative response. Chronic liver damage in BMP-9-deficient mice or in mice adenovirally overexpressing the selective BMP-9 antagonist activin-like kinase 1-Fc resulted in reduced deposition of collagen and subsequent fibrosis.Constitutive expression of low levels of BMP-9 stabilises hepatocyte function in the healthy liver. Upon HSC activation, endogenous BMP-9 levels increase in vitro and in vivo and high levels of BMP-9 cause enhanced damage upon acute or chronic injury.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Meyer, Christoph
|b 1
700 1 _ |a König, Courtney
|0 P:(DE-He78)5ef958977fa3c0658679b496419ce762
|b 2
700 1 _ |a Gaitantzi, Haristi
|b 3
700 1 _ |a Addante, Annalisa
|b 4
700 1 _ |a Thomas, Maria
|b 5
700 1 _ |a Wiercinska, Eliza
|b 6
700 1 _ |a Cai, Chen
|b 7
700 1 _ |a Li, Qi
|b 8
700 1 _ |a Wan, Fengqi
|b 9
700 1 _ |a Hellerbrand, Claus
|b 10
700 1 _ |a Valous, Nektarios
|0 P:(DE-He78)01ddf9bd69d91bd4b1dbef36f9427f36
|b 11
|u dkfz
700 1 _ |a Hahnel, Maximilian
|b 12
700 1 _ |a Ehlting, Christian
|b 13
700 1 _ |a Bode, Johannes G
|b 14
700 1 _ |a Müller-Bohl, Stephanie
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Klingmüller, Ursula
|0 P:(DE-He78)860df4ab16c373fb28a815dcd81107a6
|b 16
700 1 _ |a Altenöder, Jutta
|b 17
700 1 _ |a Ilkavets, Iryna
|b 18
700 1 _ |a Goumans, Marie-José
|b 19
700 1 _ |a Hawinkels, Lukas J A C
|b 20
700 1 _ |a Lee, Se-Jin
|b 21
700 1 _ |a Wieland, Matthias
|0 P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc
|b 22
700 1 _ |a Mogler, Carolin
|b 23
700 1 _ |a Ebert, Matthias P
|b 24
700 1 _ |a Herrera, Blanca
|b 25
700 1 _ |a Augustin, Hellmut
|0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
|b 26
700 1 _ |a Sánchez, Aránzazu
|b 27
700 1 _ |a Dooley, Steven
|b 28
700 1 _ |a Ten Dijke, Peter
|b 29
773 _ _ |a 10.1136/gutjnl-2016-313314
|g Vol. 66, no. 5, p. 939 - 954
|0 PERI:(DE-600)1492637-4
|n 5
|p 939 - 954
|t Gut
|v 66
|y 2017
|x 1468-3288
909 C O |p VDB
|o oai:inrepo02.dkfz.de:120514
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)5ef958977fa3c0658679b496419ce762
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)01ddf9bd69d91bd4b1dbef36f9427f36
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)860df4ab16c373fb28a815dcd81107a6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GUT : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b GUT : 2015
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l Vaskuläre Onkologie und Metastasierung
|x 0
920 1 _ |0 I:(DE-He78)B200-20160331
|k B200
|l Systembiologie der Signaltransduktion
|x 1
920 1 _ |0 I:(DE-He78)D120-20160331
|k D120
|l Angewandte Tumor-Immunität
|x 2
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a I:(DE-He78)B200-20160331
980 _ _ |a I:(DE-He78)D120-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21